Vizsgálati helyszín
AZ KLINA
Brasschaat, 2930, BelgiumMég nincs intézményhez kötve
- 13futó vizsgálat
- 12lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 25 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis2 vizsgálat
- 4. fázis2 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Lezárult11 vizsgálat
- Fut, nem toboroz8 vizsgálat
- Toboroz5 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- University Hospital, Antwerp4 vizsgálat
- Hoffmann-La Roche3 vizsgálat
- Abivax S.A.2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- Janssen Research & Development, LLC2 vizsgálat
- és még 12
Futó vizsgálatok
Toboroz
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
NCT07363044· Alimentiv Inc.· Forrás
Contact: Evi Van Dyck, Dr
Toboroz
Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma
NCT06691425· Cancer Research Antwerp· Forrás
Contact: Wim Demey, MD, PhD (principal investigator)
Fut, nem toboroz
Remote MS Care in Antwerp
NCT06179758· University Hospital, Antwerp· Forrás
Toboroz
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Forrás
Toboroz
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
NCT05701241· 4. fázis· University Hospital, Antwerp· Forrás
Contact: Wim Demey
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
ABTECT - Maintenance
NCT05535946· 3. fázis· Abivax S.A.· Forrás
Toboroz
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
NCT05169593· 4. fázis· Universitaire Ziekenhuizen KU Leuven· Forrás
Contact: Evi Van Dyck, MD
Toboroz
FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients
NCT07558083· 3. fázis· University Hospital, Antwerp· Forrás
Contact: Sanne Wouters
Fut, nem toboroz
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 3 study to see the benefit and safety of Luspatercept in comparison with Epoetin Alfa to treat anaemia due to very low, low or intermediate risk Myelodysplastic Syndromes (MDS) in people who have
not taken erythropoiesis-stimulating agents (ESA's) before and who require red blood cell transfusions.
2022-501485-22-00· 3. fázis· Celgene Corp.· Forrás
Fut, nem toboroz
ASPIRIN Trial Belgium
NCT03464305· 3. fázis· University Hospital, Antwerp· Forrás
Fut, nem toboroz
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
NCT01924819· 2/3. fázis· Australasian Gastro-Intestinal Trials Group· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Toboroz
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
NCT05642780· 2. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.· Forrás
Lezárult
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203· 3. fázis· Abivax S.A.· Forrás
Lezárult
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
NCT04941768· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Forrás
Leállították
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· 3. fázis· Biogen· Forrás
Lezárult
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· 3. fázis· AbbVie· Forrás
Lezárult
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
NCT04083976· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT03778931· 3. fázis· Stemline Therapeutics, Inc.· Forrás
Lezárult
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207· Hoffmann-La Roche· Forrás
Lezárult
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
NCT03593590· Hoffmann-La Roche· Forrás
Lezárult
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03524092· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
NCT03518086· 3. fázis· Eli Lilly and Company· Forrás
Hibát jelzek